Edelmuth Diogo G L, Leão Renata V, Filho Eduardo N K, Souza Marcio N P, Calderaro Marcelo, Kranz Peter G
From the Hospital das Clínicas da Faculdade de Medicina da Universidade de São Paulo (D.G.L.E., R.V.L., M.N.P.S., M.C.), São Paulo, SP, Brazil
Department of Radiology (D.G.L.E., R.V.L., E.N.K.F.), Hospital Sírio-Libanês, São Paulo, SP, Brazil.
AJNR Am J Neuroradiol. 2025 Feb 3;46(2):401-407. doi: 10.3174/ajnr.A8436.
Lateral decubitus CT myelography (LDCTM) is one of the main studies for the detection of CSF-venous fistulas, but detection of CSF-venous fistulas is dependent on intrathecal contrast attenuation. The purpose of this investigation was to assess the tolerability and technical performance of increased intrathecal doses of myelographic contrast compared with standard doses.
This is a retrospective series of 24 patients who underwent LDCTM following administration of either 10 or 20 mL of intrathecal iodinated contrast media (300 or 320 mg/mL of iodine content). Patients were scanned in the initial lateral decubitus position and then turned to the contralateral side and re-scanned in the same session. The safety and tolerability of the 20 mL dose was assessed from clinical records. The technical performance of the studies was compared between groups (10 or 20 mL) by measuring attenuation values over the lateral thecal sac at standardized levels. Both the initial scan and the scan after turning the patient to the contralateral side were assessed.
No moderate or severe adverse event was recorded in either group. The 20-mL group showed higher attenuation values, which were statistically greater on the second side examined compared with the standard-dose group.
Increased volume of intrathecal contrast was well-tolerated and improved the technical performance of LDCTM in this limited series. Further assessment of the safety and impact on diagnostic yield using larger patient cohorts is warranted.
侧卧CT脊髓造影(LDCTM)是检测脑脊液静脉瘘的主要检查方法之一,但脑脊液静脉瘘的检测依赖于鞘内造影剂的衰减。本研究的目的是评估与标准剂量相比,增加鞘内造影剂剂量的耐受性和技术性能。
这是一项回顾性研究,纳入24例接受LDCTM检查的患者,鞘内注射10或20 mL碘化造影剂(碘含量300或320 mg/mL)。患者先在初始侧卧位置进行扫描,然后转向对侧并在同一会诊期间再次扫描。根据临床记录评估20 mL剂量的安全性和耐受性。通过测量标准化水平下外侧硬膜囊的衰减值,比较两组(10或20 mL)研究的技术性能。对初始扫描和患者转向对侧后的扫描均进行评估。
两组均未记录到中度或重度不良事件。20 mL组显示出更高的衰减值,在检查的对侧,其衰减值在统计学上高于标准剂量组。
在这个有限的系列研究中,增加鞘内造影剂的体积耐受性良好,并改善了LDCTM的技术性能。有必要使用更大的患者队列进一步评估安全性及其对诊断率的影响。